vTv Therapeutics Inc.

NasdaqCM:VTVT Stock Report

Market Cap: US$408.0m

vTv Therapeutics Valuation

Is VTVT undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of VTVT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: Insufficient data to calculate VTVT's future cash flow value for valuation analysis.

Significantly Below Future Cash Flow Value: Insufficient data to calculate VTVT's future cash flow value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for VTVT?

Key metric: As VTVT is barely profitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for VTVT. This is calculated by dividing VTVT's market cap by their current revenue.
What is VTVT's PS Ratio?
PS Ratio11.1x
SalesUS$36.84m
Market CapUS$408.02m

Price to Sales Ratio vs Peers

How does VTVT's PS Ratio compare to its peers?

The above table shows the PS ratio for VTVT vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average29.2x
PRLD Prelude Therapeutics
24.9x34.24%US$416.5m
OVID Ovid Therapeutics
63.9x64.09%US$455.4m
VSTM Verastem
10.7x40.38%US$529.9m
ACOG Alpha Cognition
17.1x44.92%US$185.1m
VTVT vTv Therapeutics
11.1x-4.20%US$408.0m

Price-To-Sales vs Peers: VTVT is good value based on its Price-To-Sales Ratio (11.1x) compared to the peer average (29.2x).

Historical Price to Sales Ratio

Historical Price to Sales Ratio compares a stock's price to its sales over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Sales Ratio vs Industry

How does VTVT's PS Ratio compare vs other companies in the US Biotechs Industry?

119 CompaniesPrice / SalesEstimated GrowthMarket Cap
BIIB Biogen
3.1x2.27%US$30.41b
BMRN BioMarin Pharmaceutical
3.6x10.31%US$11.52b
LEGN Legend Biotech
3.8x17.29%US$4.31b
BCRX BioCryst Pharmaceuticals
2.7x8.30%US$2.36b
VTVT 11.1xIndustry Avg. 11.3xNo. of Companies119PS01632486480+
119 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: VTVT is good value based on its Price-To-Sales Ratio (11.1x) compared to the US Biotechs industry average (11.3x).

Price to Sales Ratio vs Fair Ratio

What is VTVT's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

VTVT PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio11.1x
Fair PS Ratio1.4x

Price-To-Sales vs Fair Ratio: VTVT is expensive based on its Price-To-Sales Ratio (11.1x) compared to the estimated Fair Price-To-Sales Ratio (1.4x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst VTVT forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$32.88
US$54.33
+65.25%
14.56%US$67.00US$44.00n/a6
Jul ’27US$35.05
US$53.00
+51.21%
15.13%US$67.00US$44.00n/a6
Jun ’27US$34.30
US$53.00
+54.52%
15.13%US$67.00US$44.00n/a6
May ’27US$31.69
US$53.33
+68.32%
14.47%US$67.00US$44.00n/a6
Apr ’27US$40.53
US$53.33
+31.59%
14.47%US$67.00US$44.00n/a6
Mar ’27US$38.16
US$51.20
+34.17%
21.05%US$67.00US$35.00n/a5
Feb ’27US$35.41
US$51.20
+44.59%
21.05%US$67.00US$35.00n/a5
Jan ’27US$39.99
US$40.67
+1.69%
12.10%US$47.00US$35.00n/a3
Dec ’26US$23.50
US$37.00
+57.45%
5.84%US$40.00US$35.00n/a3
Nov ’26US$21.75
US$35.50
+63.22%
1.41%US$36.00US$35.00n/a2
Oct ’26US$24.00
US$35.50
+47.92%
1.41%US$36.00US$35.00n/a2
Sep ’26US$16.24
US$35.50
+118.60%
1.41%US$36.00US$35.00n/a2
Aug ’26US$14.58
US$35.50
+143.57%
1.41%US$36.00US$35.00n/a2
Jul ’26US$14.67
US$35.50
+141.99%
1.41%US$36.00US$35.00US$35.052
Jun ’26US$15.89
US$35.50
+123.41%
1.41%US$36.00US$35.00US$34.302
May ’26US$20.51
US$35.50
+73.09%
1.41%US$36.00US$35.00US$31.692
US$54.33
Fair Value
39.5% undervalued intrinsic discount
6
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/19 19:08
End of Day Share Price 2026/07/17 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

vTv Therapeutics Inc. is covered by 12 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
James MolloyAlliance Global Partners
Douglas BuchananBrean Capital Historical (Janney Montgomery)
Kambiz YazdiBTIG